West Pharmaceutical Services, Inc. earnings per share and revenue
On Oct 23, 2025, WST reported earnings of 1.96 USD per share (EPS) for Q3 25, beating the estimate of 1.69 USD, resulting in a 15.40% surprise. Revenue reached 804.60 million, compared to an expected 795.81 million, with a 1.10% difference. The market reacted with a +10.92% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 16 analysts forecast an EPS of 1.85 USD, with revenue projected to reach 802.32 million USD, implying an decrease of -5.61% EPS, and decrease of -0.28% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
CONMED Corporation
Report Date
Jan 28, 2026 For Q4 25
Estimate
$1.34
Actual
$1.43
Surprise
+5.94%
Pro-Dex Inc New
Report Date
Jan 29, 2026 For Q2 26
Estimate
$0.60
Actual
$0.66
Surprise
+9.67%
FAQ
What were West Pharmaceutical Services, Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, West Pharmaceutical Services, Inc. reported EPS of $1.96, beating estimates by 15.4%, and revenue of $804.60M, 1.1% above expectations.
How did the market react to West Pharmaceutical Services, Inc.'s Q3 2025 earnings?
The stock price moved up 10.92%, changed from $277.00 before the earnings release to $307.25 the day after.
When is West Pharmaceutical Services, Inc. expected to report next?
The next earning report is scheduled for Feb 12, 2026.
What are the forecasts for West Pharmaceutical Services, Inc.'s next earnings report?
Based on 16
analysts, West Pharmaceutical Services, Inc. is expected to report EPS of $1.85 and revenue of $802.32M for Q4 2025.